{
    "clinical_study": {
        "@rank": "82184", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This study is a regulatory post-marketing surveillance in Japan, and it is a local\n      prospective and observational study of patients who have received EYLEA for Age-Related\n      Macular Degeneration (AMD).\n\n      The objective of this study is to assess safety and effectiveness of EYLEA using in real\n      clinical practice.\n\n      A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational\n      period. An annual follow-up survey will be conducted for 5 years at the longest after\n      standard observational period."
        }, 
        "brief_title": "EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who received EYLEA for AMD\n\n        Exclusion Criteria:\n\n          -  Patients who have already received EYLEA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with subfovear choroidal neovascular age-related macular degeneration"
            }
        }, 
        "enrollment": {
            "#text": "4000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756248", 
            "org_study_id": "15895", 
            "secondary_id": "EYL-AMD"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with EYLEA under practical manner for AMD.", 
            "intervention_name": "Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EYLEA", 
            "Age-Related Macular Degeneration"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Drug Use Investigation of EYLEA for AMD", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse drug reactions(ADRs) and infections from the first intravitreal(ITV) injection of EYLEA", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Number of participants with serious adverse events (SAEs) and ocular adverse events(AEs) (especially AEs due to ITV injection procedure) from the first ITV injection of EYLEA", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756248"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with ADRs, SAEs and ocular AEs ( especially AEs due to ITV injection procedure) in subpopulations of patients background characteristics and status of EYLEA treatments from the first ITV injection of EYLEA", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Mean changes in visual acuity", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6, 24 or 36 months"
            }, 
            {
                "measure": "Proportion of patients who maintained visual acuity(corresponding to <15 letters of Early Treatment Diabetic Retinopathy Study(ETDRS) from baseline) and improved visual acuity(corresponding to >0 letter of ETDRS from baseline)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Mean changes in visual acuity in subpopulations of patients background characteristics and status of EYLEA treatments", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6, 24 or 36 months"
            }, 
            {
                "measure": "Number and intervals of ITV injection of EYLEA", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}